Sanofi enlists Emcure for cancer-drug marketing in India

Shailesh Ayyangar

Sanofi's ($SNY) known for its emerging-markets prowess, but we all need a little help sometimes. To aid it with marketing its oncology lineup in India, the French drugmaker has brought on local company Emcure Pharmaceuticals, PMLiVE reports. Emcure will be responsible for drugs Taxotere, Jevtana, Fludara and Fasturtec, and doctors and patients "will now have access--under one roof--to one of the most comprehensive and complementing oncology portfolios in India," Shailesh Ayyangar, head of Sanofi's Indian subsidiary, told the publication. Report | More

Suggested Articles

With a brand new approval for Adakveo under its belt, Novartis Sunday flaunted an analysis showing the drug could cut patient hospitalizations by 40%.

BeiGene only just won its first Brukinsa nod in MCL. But it’s already pushing to join the CLL field, and Sunday it rolled out more data.

How long can one infusion of CAR-T drug Yescarta continue helping patients with refractory large B-cell lymphoma? Pretty long, Gilead showed Saturday.